Pierluigi Tricoci

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
  2. ncbi request reprint Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 99:1389-93. 2007
  3. ncbi request reprint Present and evolving role of eptifibatide in the treatment of acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 5:401-12. 2007
  4. ncbi request reprint Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative)
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Am J Cardiol 98:30Q-35Q. 2006
  5. ncbi request reprint Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology and the Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina USA
    Am J Cardiol 98:1172-6. 2006
  6. doi request reprint GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Pierluigi Tricoci
    Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Cardiol Rev 16:89-94. 2008
  7. doi request reprint Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?
    Pierluigi Tricoci
    Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27705, USA
    Curr Opin Cardiol 23:585-90. 2008
  8. doi request reprint Scientific evidence underlying the ACC/AHA clinical practice guidelines
    Pierluigi Tricoci
    Division of Cardiology and Duke Clinical Research Institute, Duke University, Durham, North Carolina 27705, USA
    JAMA 301:831-41. 2009
  9. doi request reprint Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, NC, USA
    Eur Heart J 34:1723-31. 2013
  10. doi request reprint Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevatio
    Akshay Bagai
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    Am Heart J 166:466-73. 2013

Detail Information

Publications33

  1. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  2. ncbi request reprint Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 99:1389-93. 2007
    ..In conclusion, in this observational analysis, overall ischemic outcomes were similar between the 2 groups, but clinical trials are needed to solve the controversy over optional timing of GP IIb/IIIa inhibitor use...
  3. ncbi request reprint Present and evolving role of eptifibatide in the treatment of acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 5:401-12. 2007
    ....
  4. ncbi request reprint Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative)
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Am J Cardiol 98:30Q-35Q. 2006
    ..This article reviews the major results from the CRUSADE initiative on risk stratification, gaps in guidelines adherence, paradoxical care, and the association of guideline adherence with outcomes...
  5. ncbi request reprint Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology and the Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina USA
    Am J Cardiol 98:1172-6. 2006
    ..In conclusion, despite the overall increase in the use of early catheterization, the gap between the use of an early invasive strategy in the highest and lowest risk patients remains large and tends to increase over time...
  6. doi request reprint GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Pierluigi Tricoci
    Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Cardiol Rev 16:89-94. 2008
    ..The availability of new antiplatelet and antithrombotic drugs renders even more complex the question of the best strategy...
  7. doi request reprint Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?
    Pierluigi Tricoci
    Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina 27705, USA
    Curr Opin Cardiol 23:585-90. 2008
    ..We also discuss the implication of timing in the overall management of the non-ST-segment elevation acute coronary syndrome patients...
  8. doi request reprint Scientific evidence underlying the ACC/AHA clinical practice guidelines
    Pierluigi Tricoci
    Division of Cardiology and Duke Clinical Research Institute, Duke University, Durham, North Carolina 27705, USA
    JAMA 301:831-41. 2009
    ....
  9. doi request reprint Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, NC, USA
    Eur Heart J 34:1723-31. 2013
    ..In this analysis, we explored the effect of vorapaxar on myocardial infarction (MI)...
  10. doi request reprint Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevatio
    Akshay Bagai
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    Am Heart J 166:466-73. 2013
    ..We sought to further explore this finding using methods for examination of treatment effect in this postrandomization subgroup...
  11. doi request reprint Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 162:884-892.e1. 2011
    ..Dose adjustment of renally excreted antithrombotic drugs is recommended for patients with reduced renal function. We examined the influence of dose modification on bleeding and efficacy...
  12. doi request reprint Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 366:20-33. 2012
    ..Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation...
  13. doi request reprint A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Heart 99:1282-7. 2013
    ..To reassess the efficacy of cangrelor efficacy using the universal definition of myocardial infarction (MI)...
  14. ncbi request reprint Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge
    Pierluigi Tricoci
    Division of Cardiology, Duke University School of Medicine, and Duke Clinical Research Institute, Durham, NC, USA
    Arch Intern Med 166:806-11. 2006
    ....
  15. doi request reprint Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 62:242-51. 2013
    ....
  16. doi request reprint Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC, USA
    Circ Cardiovasc Qual Outcomes 5:205-13. 2012
    ..Regional differences in the profile and prognosis of non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients treated with medical management after angiography remain uncertain...
  17. doi request reprint Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:448-58. 2011
    ..We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials...
  18. doi request reprint Promises of PAR-1 inhibition in acute coronary syndrome
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705, USA
    Curr Cardiol Rep 14:32-9. 2012
    ..In this review we discuss the rationale for developing this novel class of agents with a focus on the two compounds in most advanced clinical development, vorapaxar (SCH 530348) and atopaxar (E5555)...
  19. ncbi request reprint The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    J Interv Cardiol 19:449-55. 2006
    ..This review discusses, in the light of clinical trials recently presented, what we know, what we are learning, and what we still need to learn...
  20. doi request reprint Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 60:2296-304. 2012
    ..This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI...
  21. doi request reprint Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
    Tracy Y Wang
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Circulation 123:722-30. 2011
    ..This analysis examines efficacy and safety of early eptifibatide in the setting of concurrent upstream clopidogrel use...
  22. doi request reprint Novel anti-platelet agents: focus on thrombin receptor antagonists
    Flavio de Souza Brito
    Duke Clinical Research Institute, Durham, NC, USA
    J Cardiovasc Transl Res 6:415-24. 2013
    ..In this review, we will describe the pharmacology of PAR-1 antagonists and will review and discuss results of randomized clinical trials with PAR-1 antagonists...
  23. doi request reprint Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA Electronic address
    Int J Cardiol 168:2510-7. 2013
    ....
  24. doi request reprint Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Int J Cardiol 167:2580-7. 2013
    ..We evaluated the efficacy and safety of intensive treatment with glycoprotein IIb/IIIa inhibitors in an elderly population, and the relationships between age, timing of administration, and clinical outcomes...
  25. doi request reprint Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Adv Cardiol 47:87-99. 2012
    ..In this chapter we will discuss the rationale for developing this novel class of antiplatelet agents and specifically, the two compounds in most advanced clinical development, vorapaxar and atopaxar...
  26. doi request reprint Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes
    Jonathan P Piccini
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27705, USA
    Circulation 126:41-9. 2012
    ..However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described...
  27. doi request reprint Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555
    Sergio Leonardi
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Drugs 70:1771-83. 2010
    ..In this review we discuss this novel class of antiplatelet agents, focusing in particular on their therapeutic potential...
  28. doi request reprint A new generation of antiplatelet agents
    Matthew B Sellers
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Curr Opin Cardiol 24:307-12. 2009
    ..This article discusses potential new targets for platelet inhibition and reviews innovative antiplatelet therapies under investigation...
  29. ncbi request reprint Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida
    Manesh R Patel
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 149:1009-19. 2005
  30. pmc Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
    Jennifer Vergara-Jimenez
    Department of Medicine Cardiology, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Vasc Health Risk Manag 6:39-45. 2010
    ..In this article we review the most relevant data from randomized clinical trials with abciximab in patients undergoing PCI and discuss the recent guideline recommendation on use during PCI...
  31. doi request reprint Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 121:1713-21. 2010
    ..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
  32. ncbi request reprint Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Red
    Pierluigi Tricoci
    Circulation 112:e282; author reply e283. 2005
  33. ncbi request reprint Clinical use of novel antithrombotic agents in the management of acute coronary syndromes
    Giovanni Melandri
    Institute of Cardiology, Bologna University, Italy
    Pathophysiol Haemost Thromb 32:282-8. 2002
    ..All patients with glomerular filtration rate > or = 30 ml/min should receive low molecular weight heparin. Evidence for that is mainly driven by studies using enoxaparin...